GE HealthCare Technologies and the Mayo Clinic announced the GEMINI‑RT initiative on December 3 2025, a joint research collaboration aimed at developing personalized radiation therapy solutions that integrate advanced imaging, artificial intelligence, and real‑time patient monitoring.
The partnership builds on a 2023 collaboration that focused on AI‑enabled imaging for oncology. Mayo’s extensive clinical expertise and patient‑outcome data complement GE’s engineering capabilities in radiation delivery and imaging, creating a platform that can tailor radiation doses to individual tumor biology across the entire patient journey.
GEMINI‑RT will explore integrated solutions from detection and diagnosis through treatment planning, delivery, and follow‑up. By combining high‑resolution imaging, AI‑driven segmentation, and adaptive planning algorithms, the initiative seeks to improve treatment efficacy while reducing side effects through real‑time monitoring and dose adjustment.
Strategically, the collaboration expands GE’s oncology ecosystem and positions the company to capture a growing share of the global cancer‑treatment market. The initiative aligns with GE’s precision‑care strategy, potentially opening new revenue streams in AI‑enabled radiation planning and delivery, and reinforcing its competitive stance against other technology providers.
"GEMINI‑RT is grounded in the concept of ‘twinning the patient, personalizing the beam,’" said Dr. Bryan Traughber, Vice Chair of Innovation for Radiation Oncology at Mayo Clinic. "The combination of research and technological acumen will allow us to model individual patient journeys with precision, enabling truly tailored radiation therapy.”
Kelly Londy, President and CEO of GE HealthCare’s MR division, added that the partnership reflects GE’s broader commitment to advancing MR‑based radiation oncology workflows, underscoring the company’s focus on high‑precision treatment planning.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.